Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Commentary|Articles|July 21, 2026
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
Author(s)Tyler Garman, MD
Fact checked by: Hannah Clarke, Cheney Gazzam Baltz
Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG-naive NMIBC.
Advertisement
Advertisement
As ongoing BCG shortages continue to challenge the management of high-risk non–muscle-invasive bladder cancer (NMIBC), interest has grown in alternative first-line intravesical treatment strategies. Updated findings from the phase 2 GEMDCE trial (NCT04386746) of first-line intravesical gemcitabine and docetaxel (gem/doce) showed durable 3-year high-grade recurrence-free survival, no progression during treatment, and a manageable safety profile in patients with BCG-naive high-risk NMIBC.1
Related to this article
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Mark D. Tyson II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
These FAQs outline key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Advertisement
Advertisement